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Abstract
Introduction: During human pregnancy, circulating concentrations of components of the renin–angiotensin system
increase, but pressor refractoriness to angiotensin II (Ang-II) is observed. Given the importance of the Ang-II pressor
response in deciding susceptibility to preeclampsia and of the Ang-II system for controlling uterine vasoreactivity, we
sought to address the effects of pregnancy on the reactivity of the isolated uterine artery (UA) in mice.
Materials and methods: Blood pressure was measured throughout pregnancy in awake C57BL/6J mice. UA segments were
isolated from three groups of animals (non-pregnant, mid [day 12–13] and late [day 18–19] gestation) and studied by
wire myography.
Results: UA diameters, KCl-mediated responses, and acetylcholine-dependent vasorelaxation were greater at mid and
late gestation than in non-pregnant animals. Ang-II responses were also greater during pregnancy, with an increased
contraction in response to AT2 receptor blockade at mid-gestation. AT1 receptor blockade abolished the Ang-II
response in all groups.
Conclusions: Study findings are consistent with the possibility that AT2 receptor-mediated vasodilatation plays a role in
modulating Ang-II contractile responses in pregnancy.
Keywords
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Introduction
The uterine artery (UA) and uterine circulation in general
make major contributions to the decline in systemic vascular
resistance during pregnancy.1 In human pregnancy at term,
total uteroplacental flow increases approximately 50-fold,
representing nearly 20% of the cardiac output (CO).2-4 As
part of the maternal cardiovascular responses to pregnancy,
the UA undergoes pronounced vasodilatation, growth and
remodelling in all species studied to date. Integral to these
changes are the UA’s increased vasodilator response to flow
and pharmacological agonists, greater DNA production,
increased proliferative response of UA vascular smooth
muscle cells, increased force-generating capacity of the UA
smooth muscle, outward hypertrophic remodelling and consequent enlargement in luminal diameter.2,5-8
The renin–angiotensin system (RAS) affects both
vasoactive and vascular growth and remodelling-related
processes in the systemic as well as the uteroplacental circulations. One of its most important components is the
octapeptide angiotensin II (Ang-II), whose actions are
mediated by type 1 (AT1) and type 2 (AT2) membrane
receptors. The use of non-peptide blockers9 has shown that

most of Ang-II’s vasoconstrictor effects are mediated by the
AT1 receptor,10 whereas the AT2 receptor has been shown
in several animal models and human studies to oppose
AT1’s effects by causing vasodilatation and natriuresis.11-13
Several observations point to an important role for the
RAS during pregnancy in both the systemic and uteroplacental circulations. In humans, plasma levels of Ang-II and
other components of the RAS are increased; however, the
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systemic pressor response to Ang-II is reduced.14,15 The
absence of a blunted pressor response to Ang-II is among
the few predictors of susceptibility for preeclampsia,15,16
underscoring the importance of the RAS in this still poorly
understood disease. In sheep, Ang-II vasoconstricts the
uterine circulation, but the uterine compared with the systemic vascular bed is relatively refractory to Ang-II. One
reason for this may be that pregnancy increases UA AT2
receptor density17 above its already elevated levels in the
uterine circulation, where it comprises the majority of total
Ang-II receptors.18,19 In addition to opposing AT1-mediated
vasoconstriction, AT2 receptor activation also stimulates
nitric oxide (NO) production.20 Increased production of NO
and other endothelial substances, such as prostacyclin or
endothelium-derived hyperpolarising factor, plays important roles in increasing the vasodilator responses of the UA
and other systemic vessels during pregnancy.21-23 Given
that pregnancy increases AT2-dependent vasodilatation in
isolated rat aortae,24 and treatment with an AT2 blocker
abolishes the normal mid-pregnancy-associated fall in systemic blood pressure in mice25 and this fall in blood pressure is absent in mice lacking the expression of the Ang-II
AT2 receptor,26 we considered that AT2-mediated vasodilatation might also be an important contributor to the
pregnancy-associated increase in vasodilator response.
Recently the mouse has emerged as an important model
for studying maternal physiological responses to pregnancy,
since the availability of genetically modified strains provides unique opportunities for identifying the genes and
their mode of action on relevant cardiovascular systems.27
Similar to humans, pregnancy in the mouse decreases vascular resistance, raises CO, lowers blood pressure as well as
the pressor response to Ang-II,28,29 and directs much of the
increase in flow to the uteroplacental circulation.5 To establish the role of Ang-II receptors in modulating vascular
changes during pregnancy and, specifically, the role of the
AT2 receptor in opposing AT1-mediated vasoconstriction,25,30-32 we studied the blood pressure response to pregnancy and the effects of Ang-II as well as other agonists on
UA vasoreactivity in the mouse. We hypothesised that
enhanced AT2-mediated signalling augmented UA vasodilatation, with such augmentation being particularly evident at
mid-pregnancy or the time of greatest fall in systemic blood
pressure. To test this hypothesis we measured blood pressure
before and then throughout gestation in C57BL/6J mice and
used wire myography to compare the contractile and relaxation responses of isolated uterine vessels in non-pregnant,
mid (day 12–13) and late (day 18–19) pregnant animals.

Materials and methods
Animals

All procedures were approved by the Wake Forest
University School of Medicine Institutional Animal Care
and Use Committee. Female and male C57BL/6J mice were

obtained from Charles River Laboratories Inc, Wilmington,
MA, USA. Mice were housed in polypropylene cages in a
temperature and humidity-controlled environment. Animal
housing facilities were controlled on a 12-h light, 12-h dark
cycle and mice were given free access to standard laboratory chow and water. Non-pregnant (NP) female mice were
used between 8 and 12 weeks of age. Mature cycling female
mice (7–8 weeks old) were used for breeding purposes and
studied 2–3 weeks later; the presence of a vaginal plug was
taken as indication of day 0 of pregnancy.

Blood pressure and heart rate measurements
All mice were trained to become familiar with the computerised programmed tail-cuff blood pressure analysis system (Visitech Systems Inc, Apex, NC, USA) before the data
were collected, as previously described.25 All data were collected between 8:00 and 10:00 AM. This system permits
measuring systolic blood pressure (SBP) and heart rate
(HR) in each animal from, on average, 30 values. In NP
animals SBP and HR were recorded during four consecutive
days. After breeding, SBP and HR were recorded daily
throughout pregnancy. SBP and HR for middle gestation
(MG) were determined as the average of those measurements obtained at day 12 and 13 of pregnancy, while the
values for the late gestation (LG) group were determined as
the average of the day 18 and 19 values.

Arterial segment preparation
Female NP mice, at MG or LG were killed by cervical
dislocation, the uterine horn was removed by laparotomy
and the tissue placed directly into ice-cold Krebs buffer.
Under a dissecting microscope the main UA was identified
and dissected free from fat and connective tissue. Uterine
vessels from NP (90 µm), MG (120 µm) and LG (150 µm)
animals were cut into 1.5–2 mm segments and mounted
between an isometric force transducer (Kistler Morce DSC
6, Seattle, WA, USA) and a displacement device on a myograph (Multi Myograph, Model 610M Danish Myo
Technologies, Aarhus, Denmark) using two stainless steel
wires (diameter 25 µm). The myograph organ bath (5 ml)
was filled with Krebs buffer maintained at 37°C and aerated with 95% O2–5% CO2. The vessels were washed and
incubated for 30 min before the normalisation procedure
was performed as described.33 Each arterial segment was
stretched in a stepwise manner and the internal circumference and corresponding wall tension at each stretch were
calculated and plotted to produce a resting wall tension–
internal circumference curve for that particular artery
using the Myodaq software (National Instruments
Corporation, Denmark). Uterine segments were normalised to 0.9 of L13.3 kPa as described.33 After obtaining the
optimal diameter, a 30-min equilibration period preceded
the addition of test substances.
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Response to depolarising concentrations of KCl
In order to test the viability of the arterial preparations and
determine responses to non-receptor-mediated contraction,
segments of UA were exposed successively to increasing
concentrations of potassium chloride (KCl). Arterial segments were exposed to eight different concentrations of
KCl (6.25–62.5 mM), with each dose maintained for 2 min
and the segment washed with Krebs buffer before the subsequent concentration was introduced.

Response to U46619
To test the response to a receptor-mediated contraction,
arterial segments were exposed to a cumulative concentration-response curve of the thromboxane analogue U41669
by exposing arteries to eight (10–9–10–6.75 M) increasing
concentrations, with each subsequent dose being introduced after a steady response had been reached.

Response to angiotensin II
In order to avoid tachyphylaxis and desensitisation, Ang-II
was used only once in each arterial segment. Ang-II was
administered 30 min after the last contraction of the KCl
curve had been relaxed with Krebs buffer, the segments
washed three times, and Ang-II response was tested as the
maximal response to a single 10-7 M dose. Since the shape
of the Ang-II contraction is such that there is an initial spike
and then decline (as shown in figure 5A), we elected to
measure the contraction at the spike as this represented the
point of maximal force generation. In parallel experiments,
different arterial segments were preincubated for 15 min
with the AT1 receptor inhibitor losartan at 10-5 M or the AT2
receptor inhibitor PD123319 at 10-5 M. The Ang-II receptor
antagonists produced different effects on Ang-II contraction; losartan 10-5 M blocked most of the response, whereas
PD123319 at the same dose of 10-5 M increased the response
in the MG group.

Response to acetylcholine
A cumulative concentration-response curve for acetylcholine (ACh) was constructed by adding 13 different concentrations (ACh 10–10–10–4 M) to vessels pre-constricted with
3 × 10-8 M U46619 or 80% of the maximal constriction,
with each subsequent dose being introduced at 2-min intervals. In parallel experiments, different arterial segments
were preincubated for 15 min with the nitric oxide synthase
inhibitor L-NAME at a concentration of 10-4 M.

Solutions and drugs
Krebs buffer contained (in mM) NaCl 118.5, NaHCO3 25,
KCl 4.7, KH2PO4 1.2, MgSO4 1.2, CaCl2 2.5, and glucose
5.5 with a final pH of 7.4. In solutions used for testing KCl
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depolarising effects, NaCl was replaced by an equimolar
amount of KCl. All drugs and agonists used were obtained
from Sigma Chemical Co. (St. Louis, MO, USA).

Data analysis
Myodata 2.02 (National Instruments Corporation,
Denmark), Excel, and GraphPad Prism version 5.0
(GraphPad Software, San Diego, CA, USA) were used to
analyse the data. Concentration-response curves for KCl,
ACh and U46619 were analysed by fitting individual
experimental data to a logistic curve to determine maximal
response and sensitivity. The curve was of the form Y =
bottom + (top - bottom) / (1 +10(LogEC50 - X)* Hill Slope)) where
X is the logarithm of the concentration and Y is the response;
the EC50 values reported are derived from these fits. The
contractile response to KCl was expressed in mN/mm2 as
units of arterial wall tension (AWT) (AWT = force / 2 ×
length of vessel). For each arterial segment the maximal
response to KCl was calculated, and the response to contractile agonists was expressed as percent of the corresponding maximal response to KCl. Relaxant responses
were expressed as the percent of reduction of U46619induced contraction. Sensitivity was expressed as pD2 (pD2
= -log [EC50]) with EC50 being the concentration of agonist
producing 50% of the maximal response. Data are expressed
as mean ± SE. One-way analysis of variance (ANOVA)
with Bonferroni’s multiple comparisons was used to determine significant differences. A p < 0.05 was accepted as an
indication of statistical significance.

Results
Blood pressure and heart rate measurements
A reduction in SBP (figure 1A) is evident at mid-gestation,
starting approximately at day 10 and reaching its peak at
day 12 with a 10% maximal reduction in SBP compared
with pre-pregnant values. In late gestation (days 18 and 19)
SBP recovered to pre-pregnancy values. A similar pattern
was observed for the recordings of HR, with approximately
12% reduction in mid-gestation and recovery in late gestation (figure 1B). The averages of values at mid-gestation
(days 12 and 13) showed a statistically significant reduction
in SBP (figure 1C) and HR (figure 1D) compared with prepregnancy values, whereas there were no such differences
in late gestation.

In vitro experiments
As shown in table 1, isolated UA segments showed increasing external diameters from NP to MG and LG groups. The
optimal diameters showed an increase of 23% and 73% in
mid and late gestation compared with arteries from NP
animals.
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Table 1. Diameters and contractile responses to potassium
chloride (KCl) and U46619 in isolated segments of mice uterine
artery (UA)
Non-pregnant Mid-gestation Late gestation
(NP)
(MG)
(LG)
Animals/Arteries 5/20
Optimal diameter 166 ± 5
(OD), µm
KMAX, N/m
0.67 ± 0.09
KCl, pD2
1.73 ± 0.03
U46619MAX,
114 ± 4
%Kmax
U46619, pD2
7.92 ± 0.05

8/30
205 ± 16*

7/28
287 ± 9*†

2.04 ± 0.07*
1.78 ± 0.04
110 ± 5

2.75 ± 0.36*†
1.76 ± 0.04
101 ± 3*

7.89 ± 0.08

7.79 ± 0.08

Optimal diameter refers to diameters of UA segments measured
after the normalisation procedure. Contractile responses for KCl are
expressed as absolutes values of tension in N/m, responses for U46619
are expressed as % of maximal KCl response (KMAX); sensitivity is
expressed as pD2. Data are shown as mean ± SEM.
*p < 0.05 vs. non-pregnant; †p < 0.05 vs. mid gestation by ANOVA.

Expressed as % of Kmax, the maximal response to U46619
was significantly lower in LG compared with the NP group.
There were no changes in sensitivity at any time point
(table 1 and figure 2B).

Figure 1. Systolic blood pressure (SBP; A) and heart rate (HR;
B) in non-pregnant (NP, n = 6), mid gestation (MG, n = 11) and
late gestation (LG, n = 7) pregnant mice. Dotted vertical line
indicates day of breeding. C and D: Data correspond to the
average of 4 days for NP (white box), days 12 and 13 for MG
(black box) and days 18 and 19 for LG (grey box). Data are
shown as mean ± SEM. *p < 0.05 vs. NP and LG, † p < 0.05 vs.
LG by ANOVA.

Response to KCl and U46619. Greater maximal contraction
(Kmax) values were observed in MG or LG compared with
NP animals (table 1 and figure 2A and 4, 204% and 310%
in Kmax respectively). No significant differences were
observed in the sensitivity to KCl. The absolute values for
the contractile response to U46619 followed a similar pattern, with maximal tension values increasing progressively
with gestation (0.79 ± 0.09, 2.27 ± 0.11 and 2.54 ± 0.36 mN/
mm2 in NP, MG and LG animals, respectively, figure 3.

Response to acetylcholine. In arteries pre-constricted with a
sub maximal dose of U46619 (3 × 10-8 M) to achieve 80%
of the maximal contraction, maximal relaxation to acetylcholine (AChMAX) was greater in MG and LG compared
with the NP state (figure 4A and table 2). Sensitivity to
acetylcholine, expressed as pD2, increased as gestation
progressed (table 2). Treatment with L-NAME diminished
AChMAX in all the groups studied and decreased sensitivity
in the MG and LG groups (figure 4B and table 2).
Response to Ang-II. As shown in figure 5A, 10-7 M Ang-II
elicits a transient response. As was the case for KCl and
U46619, absolute contractile response to Ang-II was
increased during pregnancy with values of 0.5 ± 0.1, 1.7 ±
0.3 and 2.6 ± 0.5 mN/mm2 in NP, MG and LG animals,
respectively (figure 3). Pre-incubation with the AT2 receptor blocker PD123319 (10-5 M) induced a greater contraction in the MG group compared with the controls (figure
5B). No effects of AT2 receptor blockade were observed in

Table 2. Parameters of the ACh response in isolated segments of mice uterine artery (UA)

AChMAX, %
ACh pD2

Non-pregnant (NP)

Mid-gestation (MG)

Late gestation (LG)

Control

+ L-NAME

Control

+ L-NAME

Control

79 ± 6
6.62 ± 0.34

18 ± 2‡
6.49 ± 0.23

91 ± 3*
7.62 ± 0.09*

72 ± 6‡
6.98 ± 0.18‡

94 ± 4*
7.9 ± 0.06*†

+ L-NAME
84 ± 2‡
7.45 ± 0.22‡

Maximal relaxation (AChMAX) and sensitivity (ACh pD2) to acetylcholine in the UA of non-pregnant, mid gestation and late gestation pregnant mice.
Values for control arteries and arteries treated with the nitric oxide synthase inhibitor (+L-NAME 10-4 M) are shown.
* p < 0.05 vs. non-pregnant; † p < 0.05 vs. mid gestation; ‡ p < 0.05 vs. control by ANOVA.

180

Figure 2. Potassium chloride (KCl)-induced (A) and U46619induced (B) vasoconstriction in uterine arteries from
non-pregnant (NP, n = 5), mid gestation (MG, n = 8) and
late gestation (LG, n = 7) mice. Responses are expressed as
absolutes values of tension (AWT; arterial wall tension) in N/m
(A) or as % of maximal KCl response (%KMAX, B). Data are
shown as mean ± SEM. *p < 0.05 vs. NP, † p < 0.05 vs. MG, in
maximal response by ANOVA.

Journal of the Renin-Angiotensin-Aldosterone System 12(3)

Figure 3. Acetylcholine-induced relaxation in non-pregnant
(NP), mid gestation (MG) and late gestation (LG) uterine
arteries pre-constricted with 3 × 10-8 M U46619. Responses are
expressed as percentage of the contraction response.
A; response in control arteries. B; response in arteries
pre-treated with 10-4 M L-NAME. Data are shown as
mean ± SEM. * p < 0.05 vs. NP by ANOVA.

NP or LG groups. Pre-incubation of the arterial segments
with losartan 10-5 M, to inhibit AT1 receptor-mediated
responses, abolished the Ang-II response in all three groups.

Discussion

Figure 4. Maximal contractile responses of isolated uterine
artery during mouse pregnancy. Absolute maximal responses to
KCl, U46619 and Ang-II expressed as mN/mm2 in non-pregnant
(NP, n = 5), mid gestation (MG, n = 8) and late gestation (LG,
n = 7). Data are shown as mean ± SEM. # p < 0.05 vs. NP
values, * p < 0.05 vs. MG, † p < 0.05 vs. KCl.

In this study we measured BP and HR during gestation in
wild-type C57BL/6J mice and vascular reactivity in isolated UA. Our findings of a lower BP at mid-pregnancy
agreed with previous reports,25,34 while HR responses seem
more variable.28,29,34,35 Given the importance of Ang-II
responses in the uteroplacental circulation during pregnancy and the differing contributions of the AT1 and AT2
receptors in mediating this response, we studied the role of
the AT2 receptor in modulating UA Ang-II contractile
response. Our results showed that pregnancy increased the
contractile response to Ang-II in the mouse UA, and that
this contraction was further increased in the presence of the
AT2 inhibitor PD123319 at mid-gestation. We interpreted
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Figure 5. Contractile response to Ang-II in mouse uterine
artery (UA). A. Representative trace showing the response
to Ang-II in UA of a control pregnant mouse at mid gestation
compared with the response to 62.5 mM KCl (w = wash).
B. Absolute maximal response to Ang-II expressed as mN/mm2
in control arteries, arteries pre-treated with PD123319 10-5 M
and arteries pre-treated with losartan 10-5 M as indicated, in
non-pregnant (NP) (n = 5), mid gestation (MG) (n = 8) and late
gestation (LG) (n = 7) groups. Data are shown as mean ± SEM.
* p < 0.05 vs. MG control, † p < 0.05 vs. control and PD123319
treated arteries by ANOVA.

these results as supporting the likelihood that increased
AT2-mediated activity opposed the contractile effects of
Ang-II and contributed to enhanced UA vasodilatation. The
time at which the greater inhibitory effect of PD123319
was observed coincided with that at which systemic blood
pressure was lowest, suggesting that AT2 receptormediated signalling might play a more general role in
pregnancy-associated vasodilatation.
The UA undergoes significant structural and functional
changes during pregnancy.6 In particular, the UA doubles in
diameter in humans and other species,2 and increased
responses to KCl have been observed in sheep arteries.8
Similarly, we observed increased diameters and greater
responses to KCl in UA from pregnant versus non-pregnant
mice. Our values for maximal response to KCl at late gestation (2.75 ± 0.36 mN/mm2) agree with those reported for the
mice UA at equivalent gestational age (~2.5 mN/mm2).21
Increased KCl-mediated contraction during pregnancy suggests the presence of more vascular smooth muscle cells,
which in turn is likely to be due to the pregnancy-associated
increase in sensitivity of UA smooth muscle cells to proliferative stimuli.7 Unique to pregnancy is that these changes
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lead to outward hypertrophic remodelling with increased
cross-sectional area.6,36 Given these changes in smooth
muscle content, we expressed the tension developed as %
of the maximal response to KCl in order to allow the evaluation of agonist responses independent of the amount of
smooth muscle per unit of surface area. Therefore we interpret the lower contractile response to U46619 in LG arteries
as indicating an attenuation of UA constrictor responses;
this is similar to previous observations in rats,24 guinea
pigs37 and mice.29
The incomplete inhibition of the vasodilator response to
acetylcholine observed in the present study following
L-NAME treatment in pregnant UA suggests that mechanisms other than NO influence UA vasodilatation during
murine pregnancy. The importance of NO production during
pregnancy has been widely recognised. However, since
knockout mice for any of the NO synthase isoforms do not
develop hypertension,38 it appears likely that mechanisms
other than NO are also involved. Such additional vasodilators are likely to be cyclo-oxygenase products, specifically
PGI2,22,39 as well as endothelium-derived hyperpolarising
factor (EDHF).40,41 A new observation from the present study
is that AT2-mediated vasodilatation may also be involved.
The UA exhibited a different response to U46619 and
Ang-II in during pregnancy; whereas the U46619 maximal
contraction was lower in LG, we interpret the lower Ang-II
in MG as an indication of an Ang-II-specific mechanism
activated earlier in gestation. The vasoconstrictor actions of
the Ang-II system have been well studied during pregnancy,
but comparatively less attention has been devoted to its
AT2-mediated vasodilatory effects. During human pregnancy the systemic and uterine circulations become less
responsive to the contractile effects of Ang-II despite the
increases occurring in several components of the RAS.
While many factors influence the RAS, our results, showing an increased inhibitory effect of PD123319 on Ang-II
stimulation at mid-gestation, suggest a role for increased
AT2-mediated signalling that acts to oppose AT1-mediated
UA vasoconstriction at mid-pregnancy. Consistent with the
results reported here are studies showing that PD123319
blocks the mid-gestation decrease in BP in mice, and that
AT2-receptor-deficient strains lack this normal midpregnancy BP fall.25,26 The availability of AT1 and AT2
receptor knockout mice creates the possibility of further
evaluating the role of AT2-mediated signalling in lowering
peripheral vascular resistance during pregnancy. Studies of
uterine blood flow and vascular reactivity in these knockout
strains are needed to establish the mechanisms whereby the
AT2-receptor-mediated vasodilatation influences UA and
systemic vascular control during pregnancy. Information as
to whether AT2 receptor signalling is disrupted in preeclampsia would enlarge our understanding of this still poorly
understood disease, known to be a major cause of maternal
and infant morbidity and mortality. A role for AT2-mediated
signalling in decreasing BP and raising UA blood flow
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might also be a potentially important target for treating the
uteroplacental ischaemia characteristic of this disorder.42,43
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